文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

HIV感染女性的原发HPV与分子宫颈癌筛查

Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus.
PubMed 文献 · Clin Infect Dis · 2021-01-01

本研究纳入865名HIV感染女性,评估原发HPV筛查(PHS)及其反射分流的效能。PHS对癌前病变灵敏度87%,阴道镜转诊率35%;联合HPV16/18分型可减少阴道镜转诊。PHS联合反射HPV16/18分型可能成为联合检测的替代方案。

要点

  • PHS对癌前病变灵敏度87%,阴道镜转诊率35%。
  • PHS联合反射HPV16/18分型及Pap灵敏度84%,阴道镜转诊率30%。
  • PHS联合反射HPV16/18分型可减少不必要的阴道镜转诊。

核心结论

  • PHS联合反射HPV16/18分型可减少不必要的阴道镜转诊,若经证实可能作为HIV感染女性联合检测的替代方案。

研究设计与样本

  • 纳入865名HIV感染女性(323名来自WIHS队列,542名来自WIHS附属阴道镜门诊),均接受Pap和致癌HPV检测及HPV16/18分型。

主要发现

  • PHS对癌前病变灵敏度87%,阳性预测值9%,阴道镜转诊率35%。
  • PHS联合反射HPV16/18分型及Pap检测灵敏度84%,阳性预测值16%,阴道镜转诊率30%。
  • PHS仅联合HPV16/18分型阴道镜转诊率24%。
  • 联合检测灵敏度91%,阳性预测值12%,阴道镜转诊率40%。

关键数值与推荐

  • PHS对癌前病变灵敏度87%(95%CI未报告),阳性预测值9%,阴道镜转诊率35%。
  • PHS联合反射HPV16/18分型及Pap检测灵敏度84%,阳性预测值16%,阴道镜转诊率30%。
  • 联合检测灵敏度91%,阳性预测值12%,阴道镜转诊率40%。
  • p16/Ki-67免疫细胞化学阳性预测值20%,标本不足率13%。

临床怎么用

  • 在HIV感染女性中可考虑采用PHS联合反射HPV16/18分型作为筛查策略,以减少不必要的阴道镜转诊。

局限性

  • PHS在HIV感染女性中研究较少,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary human papillomavirus (HPV) screening (PHS) utilizes oncogenic human papillomavirus (oncHPV) testing as the initial cervical cancer screening method and typically, if positive, additional reflex-triage (eg, HPV16/18-genotyping, Pap testing). While US guidelines support PHS usage in the general population, PHS has been little studied in women living with HIV (WLWH). METHODS: We enrolled n = 865 WLWH (323 from the Women's Interagency HIV Study [WIHS] and 542 from WIHS-affiliated colposcopy clinics). All participants underwent Pap and oncHPV testing, including HPV16/18-genotyping. WIHS WLWH who tested oncHPV[+] or had cytologic atypical squamous cells of undetermined significance or worse (ASC-US+) underwent colposcopy, as did a random 21% of WLWH who were oncHPV[-]/Pap[-] (controls). Most participants additionally underwent p16/Ki-67 immunocytochemistry. RESULTS: Mean age was 46 years, median CD4 was 592 cells/µL, 95% used antiretroviral therapy. Seventy WLWH had histologically-determined cervical intraepithelial neoplasia grade 2 or greater (CIN-2+), of which 33 were defined as precancer (ie, [i] CIN-3+ or [ii] CIN-2 if concurrent with cytologic high grade squamous intraepithelial lesions [HSILs]). PHS had 87% sensitivity (Se) for precancer, 9% positive predictive value (PPV), and a 35% colposcopy referral rate (Colpo). "PHS with reflex HPV16/18-genotyping and Pap testing" had 84% Se, 16% PPV, 30% Colpo. PHS with only HPV16/18-genotyping had 24% Colpo. "Concurrent oncHPV and Pap Testing" (Co-Testing) had 91% Se, 12% PPV, 40% Colpo. p16/Ki-67 immunochemistry had the highest PPV, 20%, but 13% specimen inadequacy. CONCLUSIONS: PHS with reflex HPV16/18-genotyping had fewer unnecessary colposcopies and (if confirmed) could be a potential alternative to Co-Testing in WLWH.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Strickler HD, Keller MJ, Hessol NA, et al. Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021. PMID: 32881999. doi:10.1093/cid/ciaa1317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。